UroAlert - GU Oncology Weekly

April 30, 2026

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle-Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab-Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin: A Systematic Review and Network Meta-Analysis of Randomised Controlled Tria

Digital PCR-Based Uromonitor for Molecular Detection of Bladder Cancer: A Multicenter Validation Study Comparing Quantitative PCR and Urine Cytology.

Radiotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions.

Impact of asymptomatic bacteriuria on the outcomes and tolerability of Bacillus Calmette-Guérin immunotherapy.

Evolution of survival outcomes in robot-assisted radical cystectomy over 20 years of experience in a high-volume tertiary robotic center.

Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial.

Mitomycin for intravesical treatment of low-grade intermediate-risk non-muscle invasive bladder cancer.

Circulating tumor DNA as a prognostic and monitoring biomarker in urothelial cancers.

Fatty Acid Intake and Bladder Cancer Risk: A Multicenter Case-Control Study in Iran.

Detrimental effect of delayed or incomplete BCG protocols administration after trans-urethral tumor resection in patients with non-muscle-invasive bladder cancer: a systematic review.

Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in people undergoing radical cystectomy.

Addition of immune checkpoint inhibitors to intravesical BCG for high-risk BCG-naïve non-muscle invasive bladder cancer: Systematic review and meta-analysis.

Censoring patterns and inconsistent results in checkpoint inhibitor and adjuvant BCG trials for high-risk bladder cancer.

Implications of Hemoglobin, Albumin, Lymphocyte, Platelet (HALP) Score as a Predictor of Neoadjuvant Chemotherapy Response in Bladder Cancer Patients - Beyond the Abstract

Prognostic Factors and Oncological Outcomes after Trimodality Bladder-Preserving Therapy for Muscle-Invasive Bladder Cancer: A Multicenter Real-World Study - Read the Abstract

Penile & Urethral Cancers

European Association of Urology and American Society of Clinical Oncology Guidelines on Penile Cancer: A Summary of the 2026 Guidelines Update.

Assessing the density of lymph node metastasis in various inguinal regions of penile cancer using the nine-section method: A prospective study.

Early Perioperative Morbidity After Sentinel Lymph-Node Excision and Subsequent Completion Inguinal Lymph-Node Dissection in cN0 Penile Cancer.

Renal Cancer

Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials.

Recurrence Risk Stratification in Clear Cell Renal Cell Carcinoma Using TNM 2017 and WHO/ISUP Grade.

What Are the Limitations of Measuring Bladder Compliance, As the Sole Indicator of Future Risk to the Upper Urinary Tract and Renal Function? ICI-RS 2025.

Towards a better understanding of kidney CANCER: Genetically engineered mouse models and biomarkers insights.

An explainable clinical-radiomics machine learning model for preoperative prediction of WHO/ISUP nuclear grade in clear cell renal cell carcinoma.

Percutaneous Image-Guided Non-Target Renal Biopsy in Cancer Patients: A Tertiary Cancer Center Experience.

Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma.

Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study).

Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell renal cell carcinoma: results from a global real-world evidence study.

Clinical trial protocol of PODRACING: A randomized controlled trial evaluating 3D perfusion zone models for selective arterial clamping during robot-assisted partial nephrectomy.

Uncertainty-aware AI for tumor subtyping with histology and immunohistochemistry: A multi-center study in Renal Cell Carcinoma.

Node Positive Resected Renal Cell Carcinoma Portends a Poor Prognosis: Results From the Canadian Kidney Cancer Collaboration - Beyond the Abstract

Prostate Cancer

Real-world clinical outcomes in patients with biochemical recurrence after local therapy for non-metastatic prostate cancer.

Real-world treatment patterns in patients with biochemical recurrence after local prostate cancer therapy.

Development and Validation of a Multimodal AI-Based Model for Predicting Post-Prostatectomy Treatment Outcomes from Baseline Biparametric Prostate MRI.

Genetic Predictors of Progression and Skin Rash in Japanese mCSPC Patients Treated With Apalutamide: CUARTET Study.

Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancer.

Evaluating Clinically Significant Prostate Cancer with Pathology-Registered Radiomics: A Multi-Reader Assessment Using Lesion Diameter-based Simplified Segmentations on MRI.

Correlation of MRI-Derived Apparent Diffusion Coefficient (ADC) Values With Gleason Scores in Prostate Cancer and Quantitative Prostate MRI Reading.

Outcomes of stereotactic body radiotherapy for supraclavicular lymph node metastasis among patients with metastatic prostate cancer.

Phase 1 Dose-Escalation Study of [225Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry.

Factors Associated With Rectal Spacer Use in Prostate Cancer Patients Receiving Radiation Therapy.

The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1-3 prostate cancer.

Post-diagnostic Inflammatory and Insulinemic Diet and Lifestyle Patterns and Risk of Prostate Cancer-Specific Mortality in the Health Professionals Follow-up Study.

Omitting Elective Pelvic Nodes Irradiation in High Risk Prostate Cancer: Report on 43 Consecutive Elderly Patients.

The Benefits and Harms of Screening for Prostate Cancer in Adults Aged 18 Years and Older: A Systematic Review.

Utilization, Cost, and Subsequent Salvage Treatment of Ablative Therapies for Localized Prostate Cancer in the United States.

Canagliflozin Is a Novel Androgen Receptor Pathway Inhibitor for Castrate-Sensitive and Castrate-Resistant Prostate Cancer.

Real-life PI-RADS score and biochemical recurrence after local treatment of prostate cancer in Afro-Caribbean men.

Biophysical membrane responses of hypoxic prostate cancer cells depend on kindlin-2.

Combined radiomics, PI-RADS, and clinical model improve significant prostate cancer prediction and guide biopsy decision.

PRIMA: randomized prospective multicenter non-inferiority study for primary diagnosis of clinically significant PRostate cancer by PSA and MR IMAging-study protocol for a randomized diagnostic accuracy trial.

Polygenic risk score and 20-year prostate cancer-specific mortality and survival.

Neoadjuvant/adjuvant relugolix and enzalutamide for the treatment of high-risk locally advanced prostate cancer: study protocol of the RENAPCA phase Ib trial.

Phase 2 trial of pTVG-HP ± pTVG-AR DNA vaccines and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC).

Real-world treatment patterns in metastatic castration-resistant prostate cancer progressing from metastatic hormone-sensitive prostate cancer.

Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients.

Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel - A CABASTY Post Hoc Analysis Validated by Two International Prospective Phase 3 Trials.

Thrombotic Microangiopathy in Patients Treated with 177Lu-PSMA Combination Therapies.

Prognostic Value of [18F]Flotufolastat PET Using Visual RECIP in Docetaxel-Treated Metastatic Prostate Cancer.

PET Imaging of Accessible Prostate-Specific Membrane Antigen Reveals Dose-Dependent and Tumor Burden-Driven Variability.

A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer - Beyond the Abstract

Targeted and Perilesional or Systematic Biopsies in Prostate Cancer: The TARGET Clinical Trial Protocol - Beyond the Abstract

Upper Tract Tumors

Pathologic Complete Response After Enfortumab Vedotin Plus Pembrolizumab in Node-positive Upper Tract Urothelial Carcinoma.

Upper Tract Urothelial Carcinoma: An Update on Current Diagnostic Modalities and Emerging Biomarkers.

Differentiating Upper Tract Urothelial Carcinoma with Synchronous or Metachronous Bladder Cancer.

Real-world multicenter adherence to international guidelines in the management of upper tract urothelial carcinoma: insights from the ROBUUST 2.0 Registry.

Is More Better? Evaluating Neoadjuvant Chemotherapy Cycles Before Surgery for High-Risk Upper Tract Urothelial Carcinoma - Beyond the Abstract

Testicular Cancer

European Association of Urology Guidelines on Testicular Cancer: Summary of the 2026 Guidelines.

Robotic retroperitoneal surgery in a uro-oncology specialised centre: Translating RPLND expertise from testicular cancer to non-genitourinary retroperitoneal tumour resection.

Post-treatment paternity in testicular cancer survivors: Do demographic variables matter?

Presentation, management, and outcomes of testicular germ cell tumors by age.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC